Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | NNMT | P40261 | 1/20 | 0.38 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | PDE10A | Q9Y233 | 8/20 | 0.35 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.34 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | PDE2A | O00408 | 2/20 | 0.32 |
| ▸ | PDE5A | O76074 | 1/20 | 0.32 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.32 |
| ▸ | PDE11A | Q9HCR9 | 1/20 | 0.32 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17586768 | 0.79 | TXNRD1 (0.36) | KMT2ACYP1A2NNMTTXNRD1POLB | |
| SCHEMBL13266124 | 0.78 | TXNRD1 (0.35) | KMT2ACYP1A2NNMTTXNRD1POLB | |
| SCHEMBL15077335 | 0.78 | TXNRD1 (0.35) | KMT2ACYP1A2NNMTTXNRD1POLB | |
| SCHEMBL19407618 | 0.78 | TXNRD1 (0.35) | KMT2ACYP1A2NNMTTXNRD1POLB | |
| SCHEMBL19364178 | 0.78 | POLB (0.38) | KMT2ACYP1A2NNMTTXNRD1POLB | |
| SCHEMBL23547118 | 0.78 | HPGD (0.36) | KMT2ACYP1A2NNMTTXNRD1POLB | |
| SCHEMBL24967237 | 0.77 | HRH4 (0.31) | — | |
| SCHEMBL19121807 | 0.76 | CRHR1 (0.38) | — | |
| SCHEMBL12512787 | 0.76 | LMNA (0.32) | — | |
| SCHEMBL29952389 | 0.75 | POLB (0.36) | KMT2ACYP1A2NNMTTXNRD1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11814391-B2 | Macrocyclic compounds for the treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-20230032020-A1 | SMALL-MOLECULE COVALENT INHIBITION OF RAL GTPASES | NATIONAL INSTITUTES OF HEALTH | 2023-02-02 | — | — | US | disclosed |
| WO-2020156243-A1 | SHP2 INHIBITOR AND APPLICATION THEREOF | 贝达药业股份有限公司 | 2020-08-06 | — | — | WO | disclosed |
| WO-2017165255-A1 | PYRIMIDINES AND VARIANTS THEREOF, AND USES THEREFOR | AFFERENT PHARMACEUTICALS INC. (US) | 2017-09-28 | — | — | WO | disclosed |
| US-20160235748-A1 | PYRAZOLO[1,5-A]PYRIMIDINES AS ANTIVIRAL AGENTS | GILEAD SCIENCES, INC. | 2016-08-18 | — | — | US | disclosed |
| US-9278975-B2 | Pyrazolo[1,5-A]pyrimidines as antiviral agents | GILEAD SCIENCES, INC. (US) | 2016-03-08 | — | — | US | disclosed |
| US-20150166546-A1 | PYRAZOLO[1,5-A]PYRIMIDINES AS ANTIVIRAL AGENTS | GILEAD SCIENCES, INC. | 2015-06-18 | — | — | US | disclosed |
| US-8946238-B2 | Pyrazolo[1,5-A]pyrimidines as antiviral agents | GILEAD SCIENCES, INC. (US) | 2015-02-03 | — | — | US | disclosed |
| US-20130164280-A1 | PYRAZOLO[1,5-A]PYRIMIDINES AS ANTIVIRAL AGENTS | GILEAD SCIENCES, INC. (US) | 2013-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230032020-A1 | SMALL-MOLECULE COVALENT INHIBITION OF RAL GTPASES | RALA, KRAS, HRAS | KMT2A 487/4885CYP1A2 4600/4885NNMT 2517/4885 |
| US-20130164280-A1 | PYRAZOLO[1,5-A]PYRIMIDINES AS ANTIVIRAL AGENTS | TYMP, ZC3HAV1, TYMS | KMT2A 3906/4885CYP1A2 1682/4885NNMT 884/4885 |
| US-20150166546-A1 | PYRAZOLO[1,5-A]PYRIMIDINES AS ANTIVIRAL AGENTS | TYMP, ZC3HAV1, TYMS | KMT2A 3906/4885CYP1A2 1682/4885NNMT 884/4885 |
| US-20160235748-A1 | PYRAZOLO[1,5-A]PYRIMIDINES AS ANTIVIRAL AGENTS | TYMP, ZC3HAV1, TYMS | KMT2A 3906/4885CYP1A2 1682/4885NNMT 884/4885 |
| US-11814391-B2 | Macrocyclic compounds for the treatment of medical disorders | CFD, TFPI, CFH | KMT2A 4672/4885CYP1A2 3361/4885NNMT 3687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.